← Back to Search

Other

4-Aminopyridine for Skin Wounds

Phase 2
Waitlist Available
Led By John Elfar, MD
Research Sponsored by John Elfar
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks

Summary

"This trial aims to test a new treatment, 4-aminopyridine (4-AP), to see if it can help wounds heal faster in healthy adults."

Who is the study for?
This trial is for adults with chronic non-healing wounds or acute wounds. Participants should be in good health overall, aside from their wound condition.
What is being tested?
The study tests if 4-aminopyridine (4-AP), a new agent thought to be safe, can speed up the healing of wounds. Some participants will receive 4-AP while others will get a placebo for comparison.
What are the potential side effects?
While the safety profile of 4-AP is considered excellent, potential side effects are not detailed here and would depend on individual reactions to the treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Return of skin integrity and wound closure after skin punch biopsy
Secondary study objectives
The effect of 4-AP on the hair number and growth at the skin punch biopsy site.

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Group A: 4-aminopyridineActive Control1 Intervention
dalfampridine (generic) 10 mg capsule po every 12 hours
Group II: Group B: PlaceboPlacebo Group1 Intervention
Placebo-1 capsule po every 12 hours

Find a Location

Who is running the clinical trial?

John ElfarLead Sponsor
3 Previous Clinical Trials
430 Total Patients Enrolled
John Elfar, MDPrincipal InvestigatorUniversity of Arizona
4 Previous Clinical Trials
498 Total Patients Enrolled
~45 spots leftby Sep 2027